NeuVasQ

About:

NeuVasQ is a pharmaceutical restoration company.

Website: https://neuvasq.com/

Top Investors: Newton Biocapital

Description:

NeuVasQ is developing drugs to restore blood-brain barrier function in acute neurological disorders such as stroke and epilepsy, as well as neurodegenerative diseases such as Alzheimer's. It is based on discoveries about the molecular mechanisms that keep the blood-brain barrier intact (BBB). The BBB regulates the exchange of information between the vascular and central nervous systems (CNS). Increased BBB permeability, whether due to age or injury, plays a role in many neurological conditions by allowing harmful blood substances to enter the CNS. Many neurodegenerative disorders, such as Alzheimer's, as well as a variety of acute neurological conditions, such as stroke and epilepsy, are associated with BBB dysfunction.

Total Funding Amount:

20M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Gosselies, Hainaut, Belgium

Founded Date:

2021-01-01

Contact Email:

hello(AT)Neuvasq.com

Founders:

Benoit Vanhollebeke

Number of Employees:

1-10

Last Funding Date:

2021-06-24

IPO Status:

Private

Industries:

© 2025 bioDAO.ai